Skip to main content
SpringerLink
Log in

Recent news in the glioblastoma research

  • Reviews
  • Published:
Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology Aims and scope

Abstract

Glioblastoma multiforme (GBL) is the most frequent and aggressive tumor of the brain. Mean survival time of GBL patients is only 12–15 months, despite most intensive treatments. To fight this severe, still almost incurable disease, a great number of researches are recruited. Here we review the results of the GBL investigations published recently (from the end of 2013 to the first half of 2014) that ensured a considerable progress in this field of oncology. Combination of DNA and RNA sequencing and functional validation made it possible to define a somatic genomic landscape of GBL, to uncover new genetic driver alterations in GBL, and to suggest new approaches for the treatment of GBL. The results of the GBL immunotherapy are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wen P.Y., Kesari S. 2008. Malignant gliomas in adults. N. Engl. J. Med. 359, 492–507.

    Article  CAS  PubMed  Google Scholar 

  2. Hottinger A.F., Stupp R., Homicsko K. 2014. Standards of care and novel approaches in the management of glioblastoma multiforme. Clin. J. Cancer. 33, 32–39.

    CAS  Google Scholar 

  3. Purow B.W., Schiff D. 2010. Glioblastoma genetics: in rapid flux. Discov. Med. 9, 125–131.

    PubMed Central  PubMed  Google Scholar 

  4. Haynes H.R., Camelo-Piragua S., Kurian K.M. 2014. Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment. Front. Oncol. 24(4),47.

    Google Scholar 

  5. Dunn G.P., Rinne M.L., Wykosky J., Genovese G., Quayle S.N., Dunn I.F., Agarwalla P.K., Chheda M.G., Campos B., Wang A., Brennan C., Ligon K.L., Furnari F., Cavenee W.K., Depinho R.A., Chin L., Hahn W.C. 2012. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26, 756–784.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Brennan C.W., Verhaak R.G., McKenna A., Campos B., Noushmehr H., Salama S.R., Zheng S., Chakravarty D., Sanborn J.Z., Berman S.H., Beroukhim R., Bernard B., Wu C.J., Genovese G., Shmulevich I., Barnholtz-Sloan J., Zou L., Vegesna R., Shukla S.A., Ciriello G., Yung W.K., Zhang W., Sougnez C., Mikkelsen T., Aldape K., Bigner D.D., Van Meir E.G., Prados M., Sloan A., Black K.L., Eschbacher J., Finocchiaro G., Friedman W., Andrews D.W., Guha A., Iacocca M., O’Neill B.P., Foltz G., Myers J., Weisenberger D.J., Penny R., Kucherlapati R., Perou C.M., Hayes D.N., Gibbs R., Marra M., Mills G.B., Lander E., Spellman P., Wilson R., Sander C., Weinstein J., Meyerson M., Gabriel S., Laird P.W., Haussler D., Getz G. 2013. The somatic genomic landscape of glioblastoma. Cell. 155, 462–477.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Frattini V., Trifonov V., Chan J.M., Castano A., Lia M., Abate F., Keir S.T., Ji A.X., Zoppoli P., Niola F., Danussi C., Dolgalev I., Porrati P., Pellegatta S., Heguy A., Gupta G., Pisapia D.J., Canoll P., Bruce J.N., McLendon R.E., Yan H., Aldape K., Finocchiaro G., Mikkelsen T., Privé G.G., Bigner D.D., Lasorella A., Rabadan R., Iavarone A. 2013. The integrated landscape of driver genomic alterations in glioblastoma. Nat. Genet. 45, 1141–1149.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Vivanco I., Robins H.I., Rohle D., Campos C., Grommes C., Nghiemphu P.L., Kubek S., Oldrini B., Chheda M.G., Yannuzzi N., Tao H., Zhu S., Iwanami A., Kuga D., Dang J., Pedraza A., Brennan C.W., Heguy A., Liau L.M., Lieberman F., Yung W.K., Gilbert M.R., Reardon D.A., Drappatz J., Wen P.Y., Lamborn K.R., Chang S.M., Prados M.D., Fine H.A., Horvath S., Wu N., Lassman A.B., DeAngelis L.M., Yong W.H., Kuhn J.G., Mischel P.S., Mehta M.P., Cloughesy T.F., Mellinghoff I.K. 2012. Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2, 458–471.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Schonberg D.L., Bao S., Rich J.N. 2013. Genomics informs glioblastoma biology. Nat. Genet. 45, 1105–1107.

    Article  CAS  PubMed  Google Scholar 

  10. Carrasco-García E., Saceda M., Martínez-Lacaci I. 2014. Role of receptor tyrosine kinases and their ligands in glioblastoma. Cells. 3, 199–235.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Hegi M.E., Rajakannu P., Weller M. 2012. Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr. Opin. Neurol. 25, 774–779.

    Article  CAS  PubMed  Google Scholar 

  12. Kalman B., Szep E., Garzuly F., Post D.E. 2013. Epidermal growth factor receptor as a therapeutic target in glioblastoma. Neuromol. Med. 15, 420–434.

    Article  CAS  Google Scholar 

  13. Glushankova N.A. 2008. Changes in the regulation of cell-cell adhesion during tumor transformation. Biokhimija (Rus.). 73(7), 925–934.

    Google Scholar 

  14. Nelson W.J., Dickinson D.J., Weis W.I. 2013. Roles of cadherins and catenins in cell-cell adhesion and epithelial cell polarity. Prog. Mol. Biol. Transl. Sci. 116, 3–23.

    Article  CAS  PubMed  Google Scholar 

  15. Arikkath J., Peng I.F., Ng Y.G., Israely I., Liu X., Ullian E.M., Reichardt L.F. 2009. Delta-catenin regulates spine and synapse morphogenesis and function in hippocampal neurons during development. J. Neurosci. 29, 5435–5442.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Abu-Elneel K., Ochiishi T., Medina M., Remedi M., Gastaldi L., Caceres A., Kosik K.S. 2008. A delta-catenin signaling pathway leading to dendritic protrusions. J. Biol. Chem. 283(47), 32781–32791.

    Article  CAS  PubMed  Google Scholar 

  17. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444(7120), 756–760.

    Article  CAS  PubMed  Google Scholar 

  18. Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., Parada L.F. 2012. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 488(7412), 522–526.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Suvà M.L., Rheinbay E., Gillespie S.M., Patel A.P., Wakimoto H., Rabkin S.D., Riggi N., Chi S., Cahill D.P., Nahed B.V., Curry W.T., Martuza R.L., Rivera M.N., Rossetti N., Kasif S., Beik S., Kadri S., Tirosh I., Wortman I., Shalek A.K., Rozenblatt-Rosen O., Regev A., Louis D.N., Bernstein B.E. 2014. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell. 157(3), 580–594.

    Article  PubMed  Google Scholar 

  20. Auffinger B., Tobias A.L., Han Y., Lee G., Guo D., Dey M., Lesniak M.S., Ahmed A.U. 2014. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ. 7, 1119–1131.

    Article  Google Scholar 

  21. Stromskaya T.P., Rybalkina E. Yu., Kruglov S.S., Zabotina T.N., Mechetner E.B., Turkina A.G., Stavrovskaya A.A. 2008. Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib. Biokhimija (Rus.). 73(5), 36–46.

    Google Scholar 

  22. Calcagno A.M., Salcido C.D., Gillet J.P., Wu C.P., Fostel J.M., Mumau M.D., Gottesman M.M., Varticovski L., Ambudkar S.V. 2010. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J. Natl. Cancer Inst. 102(21), 1637–1652.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Guens G.P., Stavrovskaya A.A. 2010. Protein YB-1 as a mammary tumor prognostic factor. Vestn. RONTs im.N.N. Blokhina RAMN (Rus.). 21(1), 3–10.

    Google Scholar 

  24. Eliseeva I.A., Kim E.R., Gurjanov S.G., Ovchinnikov L.P., Lyabin D.N. 2011. Y-box-binding protein (YB-1) and its functions. Uspekhi Biol. Khimii (Rus.). 51, 65–132.

    Google Scholar 

  25. Stavrovskaya A., Stromskaya T., Rybalkina E., Moiseeva N., Vaiman A., Guryanov S., Ovchinnikov L., Guens G. 2012. YB-1 protein and multidrug resistance of tumor cells. Curr. Signal Transduction Therapy. 7(3), 237–246.

    Article  CAS  Google Scholar 

  26. Matsumoto K., Bay B.H. 2005. Significance of the Y-box proteins in human cancers. J. Mol. Genet. Med. 1, 11–17.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Gao Y., Fotovati A., Lee C., Wang M., Cote G., Guns E., Toyota B., Faury D., Jabado N., Dunn S.E. 2009. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. Mol. Cancer Ther. 8(12), 3276–3284.

    Article  CAS  PubMed  Google Scholar 

  28. Faury D., Nantel A., Dunn S.E., Guiot M.C., Haque T., Hauser P., Garami M., Bognár L., Hanzély Z., Liberski P.P., Lopez-Aguilar E., Valera E.T., Tone L.G., Carret A.S., Del Maestro R.F., Gleave M., Montes J.L., Pietsch T., Albrecht S., Jabado N. 2007. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J. Clin. Oncol. 25(10), 1196–1208.

    Article  CAS  PubMed  Google Scholar 

  29. Fotovati A., Abu-Ali S., Wang P.S., Deleyrolle L.P., Lee C., Triscott J., Chen J.Y., Franciosi S., Nakamura Y., Sugita Y., Uchiumi T., Kuwano M., Leavitt B.R., Singh S.K., Jury A., Jones C., Wakimoto H., Reynolds B.A., Pallen C.J., Dunn S.E. 2011. YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Res. 71(16), 5569–5578.

    Article  CAS  PubMed  Google Scholar 

  30. Zhu Z., Khan M.A., Weiler M., Blaes J., Jestaedt L., Geibert M., Zou P., Gronych J., Bernhardt O., Korshunov A., Bugner V., Lichter P., Radlwimmer B., Heiland S., Bendszus M., Wick W., Liu H.K. 2014. Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. Cell Stem Cell. 15(2), 185–198.

    Article  CAS  PubMed  Google Scholar 

  31. Sun G., Yu R.T., Evans R.M., Shi Y. 2007. Orphan nuclear receptor TLX recruits histone deacetylases to repress transcription and regulate neural stem cell proliferation. Proc. Natl. Acad. Sci. USA. 104(39), 15282–15287.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Liu H.K., Wang Y., Belz T., Bock D., Takacs A., Radlwimmer B., Barbus S., Reifenberger G., Lichter P., Schötz G. 2010. The nuclear receptor tailless induces long-term neural stem cell expansion and brain tumor initiation. Genes Dev. 24(7), 683–695.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Yan F., Alinari L., Lustberg M.E., Martin L.K., Cordero-Nieves H.M., Banasavadi-Siddegowda Y., Virk S., Barnholtz-Sloan J., Bell E.H., Wojton J., Jacob N.K., Chakravarti A., Nowicki M.O., Wu X., Lapalombella R., Datta J., Yu B., Gordon K., Haseley A., Patton J.T., Smith P.L., Ryu J., Zhang X., Mo X., Marcucci G., Nuovo G., Kwon C.H., Byrd J.C., Chiocca E.A., Li C., Sif S., Jacob S., Lawler S., Kaur B., Baiocchi R.A. 2014. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Res. 74(6), 1752–1765.

    Article  CAS  PubMed  Google Scholar 

  34. Zhao Q., Rank G., Tan Y.T., Li H., Moritz R.L., Simpson R.J., Cerruti L., Curtis D.J., Patel D.J., Allis C.D., Cunningham J.M., Jane S.M. 2009. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone, and DNA methylation in gene silening. Nat. Struct. Mol. Biol. 16, 304–311.

    Article  CAS  PubMed  Google Scholar 

  35. Kitambi S.S., Toledo E.M., Usoskin D., Wee S., Harisankar A., Svensson R., Sigmundsson K., Kalderén C., Niklasson M., Kundu S., Aranda S., Westermark B., Uhrbom L., Andäng M., Damberg P., Nelander S., Arenas E., Artursson P., Walfridsson J., Forsberg Nilsson K., Hammarström L.G., Ernfors P. 2014. Vulnerability of glioblastoma cells to catastrophic vacuolization and death induced by a small molecule. Cell. 157(2), 313–328.

    Article  CAS  PubMed  Google Scholar 

  36. Barba D., Saris S.C., Holder C., Rosenberg S.A., Oldfield E.H. 1989. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J. Neurosurg. 70(2), 175–182.

    Article  CAS  PubMed  Google Scholar 

  37. Jacobs S.K., Wilson D.J., Kornblith P.L., Grimm E.A. 1987. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: Phase I trial. Cancer Res. 46(4 Pt 2), 2101–2104.

    Google Scholar 

  38. Dillman R.O., Duma C.M., Ellis R.A., Cornforth A.N., Schiltz P.M., Sharp S.L., DePriest MC. 2009. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J. Immunother. 32(9), 914–919.

    Article  PubMed  Google Scholar 

  39. Dillman R.O., Duma C.M., Schiltz P.M., DePriest C., Ellis R.A., Okamoto K., Beutel L.D., De Leon C., Chico S. 2004. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J. Immunother. 27(5), 398–404.

    Article  PubMed  Google Scholar 

  40. Lillehei K.O., Mitchell D.H., Johnson S.D., McCleary E.L., Kruse C.A. 1991. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery. 28(1), 16–23.

    Article  CAS  PubMed  Google Scholar 

  41. Tsuboi K., Saijo K., Ishikawa E., Tsurushima H., Takano S., Morishita Y., Ohno T. 2003. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin. Cancer Res. 9(9), 3294–3302.

    PubMed  Google Scholar 

  42. Wood G.W., Holladay F.P., Turner T., Wang Y.Y., Chiga M. 2000. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV. J. Neurooncol. 48(2), 13–20.

    Google Scholar 

  43. Plautz G.E., Miller D.W., Barnett G.H., Stevens G.H., Maffett S., Kim J., Cohen P.A., Shu S. 2000. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin. Cancer Res. 6(6), 2209–2218.

    CAS  PubMed  Google Scholar 

  44. Tsurushima H., Liu S.Q., Tuboi K., Matsumura A., Yoshii Y., Nose T., Saijo K., Ohno T. 1999. Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jpn. J. Cancer Res. 90(5), 536–545.

    Article  CAS  PubMed  Google Scholar 

  45. Plautz G.E., Barnett G.H., Miller D.W., Cohen B.H., Prayson R.A., Krauss J.C., Luciano M., Kangisser D.B., Shu S. 1998. Systemic T cell adoptive immunotherapy of malignant gliomas. J. Neurosurg. 89(1), 42–51.

    Article  CAS  PubMed  Google Scholar 

  46. Sloan A.E., Dansey R., Zamorano L., Barger G., Hamm C., Diaz F., Baynes R., Wood G. 2000. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg. Focus. 9(6), e9.

    Article  CAS  PubMed  Google Scholar 

  47. Jackson C., Ruzevick J., Brem H., Lim M. 2013. Vaccine strategies for glioblastoma: progress and future directions. Immunotherapy. 5(2), 155–167.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Wong A.J., Ruppert J.M., Bigner S.H., Grzeschik C.H., Humphrey P.A., Bigner D.S., Vogelstein B. 1992. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA. 89(7), 2965–2969.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Humphrey P.A., Wong A.J., Vogelstein B., Friedman H.S., Werner M.H., Bigner D.D., Bigner S.H. 1988. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res. 48(8), 2231–2238.

    CAS  PubMed  Google Scholar 

  50. Humphrey P.A., Wong A.J., Vogelstein B., Mark J., Friedman H.S., Bigner D.D. 1990. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc. Natl. Acad. Sci. USA. 87(11), 4207–4211.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Sampson J.H., Heimberger A.B., Archer G.E., Aldape K.D., Friedman A.H., Friedman H.S., Gilbert M.R., Herndon J.E. 2nd, McLendon R.E., Mitchell D.A., Reardon D.A., Sawaya R., Schmittling R.J., Shi W., Vredenburgh J.J., Bigner D.D. 2010. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(31), 4722–4729.

    Article  PubMed Central  PubMed  Google Scholar 

  52. US NIH clinical trials registry. www.clinicaltrials.gov

  53. Lai R., Recht L.D., Reardon D.A. 2014. Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients with glioblastoma (GBM). J. Clin. Oncol. 28(Suppl. 15).

    Google Scholar 

  54. Schoor O., Hilf N., Dutoit V., Weinschenk T., Walter S., Lewandrowski P., Flohr S., Trautwein C., Gouttefangeas C., Stevanovi S., Rammensee H.-G., Beckhove P., Herold-Mende C., Dietrich P.-Y., Singh H. 2010. IMA950: A novel multi-peptide cancer vaccine for treatment of glioma. Cancer Res. 70(8) 2396.

    Google Scholar 

  55. Nikitin K.D., Baryshnikov A.Yu. 2007. Anti-tumor vaccines based on heat shock proteins. Rossiiskii Bioterapevticheskii zhurnal (Rus.). 2(6), 3–12

    Google Scholar 

  56. Srivastava P.K. 2000. Roles of heat-shock proteins in innate and adoptive immunity. Nat. Rev. Immunol. 2, 185–194.

    Article  Google Scholar 

  57. Castelli C., Ciupitu A.M., Rini F. 2001. Human HPS70 peptide complexes specifically activate anti-melanoma T cells. Cancer Res. 61, 222–227.

    CAS  PubMed  Google Scholar 

  58. Graner M.W., Cumming R.I., Bigner D.D. 2007. The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences. J. Neurosci. 27(42), 11214–11227.

    Article  CAS  PubMed  Google Scholar 

  59. Hermisson M., Strik H., Rieger J., Dichgans J., Meyermann R., Weller M. 2000. Expression and functional activity of heat shock proteins in human glioblastoma multiforme. Neurology. 54(6), 1357–1365.

    Article  CAS  PubMed  Google Scholar 

  60. Soo E.T., Yip G.W., Lwin Z.M., Kumar S.D., Bay B.H. 2008. Heat shock proteins as novel therapeutic targets in cancer. In Vivo. 22(3), 311–315.

    CAS  PubMed  Google Scholar 

  61. Graner M.W., Bigner D.D. 2005. Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neurooncol. 7(3), 260–278.

    CAS  Google Scholar 

  62. Mazzaferro V., Coppa J., Carrabba M.G., Rivoltini L., Schiavo M., Regalia E., Mariani L., Camerini T., Marchianò A., Andreola S., Camerini R., Corsi M., Lewis J.J., Srivastava P.K., Parmiani G. 2003. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. 9(9), 3235–3245.

    CAS  PubMed  Google Scholar 

  63. Baldueva I.A. 2003. Antitumor vaccines. Prakticheskaya onkologiia (Rus.). 4(3), 157–166.

    Google Scholar 

  64. Shurin M.R., Gregory M., Morris J.C., Malyguine A.M. 2010. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow? Expert Opin. Biol. Ther. 10(11), 1539–1553.

    Article  CAS  PubMed  Google Scholar 

  65. Koido S., Homma S., Okamoto M., Namiki Y., Takakura K., Uchiyama K., Kajihara M., Arihiro S., Imazu H., Arakawa H., Kan S., Komita H., Kamata Y., Ito M., Ohkusa T., Gong J., Tajiri H. 2013. Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions. Oncoimmunol. 2(9), e25994.

    Article  Google Scholar 

  66. Bregy A., Wong T.M., Shah A.H., Goldberg J.M., Komotar R.J. 2013. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat. Rev. 39(8), 891–907.

    Article  CAS  PubMed  Google Scholar 

  67. Chang C.N., Huang Y.C., Yang D.M., Kikuta K., Wei K.J., Kubota T., Yang W.K. 2011. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J. Clin. Neurosci. 18, 1048–1054.

    Article  CAS  PubMed  Google Scholar 

  68. Yamanaka R., Abe T., Yajima N., Tsuchiya N., Homma J., Kobayashi T., Narita M., Takahashi M., Tanaka R. 2003. Vaccination of recurrent glioma patients with tumour lysatepulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br. J. Cancer. 89, 1172–1179.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Yu J.S., Liu G., Ying H., Yong W.H., Black K.L., Wheeler C.J. 2014. Vaccination with tumor lysate-pulsed dendritic cells elicits antigenspecific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 64, 4973–4979.

    Article  Google Scholar 

  70. Prins R.M., Soto H., Konkankit V., Odesa S.K., Eskin A., Yong W.H., Nelson S.F., Liau L.M. 2011. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin. Cancer Res. 17, 1603–1615.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  71. Cho D.Y., Yang W.K., Lee H.C., Hsu D.M., Lin H.L., Lin S.Z., Chen C.C., Harn H.J., Liu C.L., Lee W.Y., Ho L.H. 2012. Adjuvant Immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurgery. 77(5–6), 736–744.

    Article  PubMed  Google Scholar 

  72. Fadul C.E., Fisher J.L., Hampton T.H., Lallana E.C., Li Z., Gui J., Szczepiorkowski Z.M., Tosteson T.D., Rhodes C.H., Wishart H.A., Lewis L.D., Ernstoff M.S. 2011. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal radiation chemotherapy. J. Immunother. 34, 382–389.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Phuphanich S., Wheeler C.J., Rudnick J.D., Mazer M., Wang H., Nuño M.A., Richardson J.E., Fan X., Ji J., Chu R.M., Bender J.G., Hawkins E.S., Patil C.G., Black K.L., Yu J.S. 2013. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol. Immunother. 62, 125–135.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Kashirskoe shosse, 24, Moscow, 115587, Russia

    E. Yu. Rybalkina & A. A. Stavrovskaya

  2. Institute of Gene Biology, Russian Academy of Sciences, ul. Vavilova, 34/5, Moscow, 119991, Russia

    G. V. Pavlova

Authors
  1. E. Yu. Rybalkina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. V. Pavlova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. A. Stavrovskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Yu. Rybalkina.

Additional information

Original Russian Text © E.Yu. Rybalkina, G.V. Pavlova, A.A. Stavrovskaya, 2014, published in Biologicheskie Membrany, 2014, Vol. 31, No. 6, pp. 379–391.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rybalkina, E.Y., Pavlova, G.V. & Stavrovskaya, A.A. Recent news in the glioblastoma research. Biochem. Moscow Suppl. Ser. A 9, 1–12 (2015). https://doi.org/10.1134/S1990747814060063

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S1990747814060063

Keywords

Search

Navigation